Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study

BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia™. Bendavia is a novel compound that targets the mitochondrion to treat mitochondrial dysfunction including ischemia reperfusion and microvascular injuries. This clinical study evaluated patients representing a broad range of renal functions including moderate and severely impaired patients as assessed by 24–hour creatinine clearance. During the study, patients received a single dose of Bendavia administered as an intravenous infusion over a four hour period. Safety data from the clinical trial and preliminary results demonstrate that Bendavia appears to be safe and well–tolerated at the dose evaluated, with no serious adverse events reported. Bioanalytical analyses from this and related clinical studies also showed highly predictable pharmacokinetics for Bendavia.